The influence of estrogen on nigrostriatal dopamine activity

Becker, Jill B.; Beer, Mary E.

doi:10.1016/0166-4328(86)90044-6

Cited by 158 publications

(22 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The existence of sex differences in dopamine systems are the best described: both genetic sex and ovarian hormones augment dopamine function in dorsal and ventral striatum and enhance self-administration of psychomotor stimulants, narcotics and alcohol at least in rodents (Becker, 2009; Carroll & Anker, 2010; Di Paolo, 1994; Dluzen & McDermott, 2008; Dow-Edwards, 2010; Gillies & McArthur, 2010; O'Dell & Torres, 2014). Estradiol promotes while progesterone inhibits dopamine release and the reinforcing effects of most addictive drugs (Anker & Carroll, 2011; Becker & Beer, 1986; Becker & Cha, 1989; Becker et al, 2012; Becker & Ramirez, 1981; Becker & Rudick, 1999; Castner, Xiao, & Becker, 1993; Di Paolo, 1994; Walker et al, 2012; Walker, Ray, & Kuhn, 2006; Walker, Rooney, Wightman, & Kuhn, 2000). Estradiol also alters firing rate of dopamine neurons (Chiodo & Caggiula, 1983; Zhang, Yang, Yang, Jin, & Zhen, 2008).…”

Section: Sex/gender Differences In the Neurobiology Of Addictionmentioning

confidence: 99%

Emergence of sex differences in the development of substance use and abuse during adolescence

Kuhn

2015

Pharmacology & Therapeutics

148

109

View full text Add to dashboard Cite

Substance use and abuse begins during adolescence. Male and female adolescent humans initiate use at comparable rates, but males increase use faster. In adulthood, more men than women use and abuse addictive drugs. However, some women progress more rapidly from initiation of use to entry into treatment. In animal models, adolescent males and females consume addictive drugs similarly. However, reproductively mature females acquire self-administration faster, and in some models, escalate use more. Sex/gender differences exist in neurobiologic factors mediating both reinforcement (dopamine, opioids) and aversiveness (CRF, dynorphin), as well as intrinsic factors (personality, psychiatric co-morbidities) and extrinsic factors (history of abuse, environment especially peers and family) which influence the progression from initial use to abuse., Many of these important differences emerge during adolescence, and are moderated by sexual differentiation of the brain. Estradiol effects which enhance both dopaminergic and CRF-mediated processes contribute to the female vulnerability to substance use and abuse. Testosterone enhances impulsivity and sensation seeking in both males and females. Several protective factors in females also influence initiation and progression of substance use including hormonal changes of pregnancy as well as greater capacity for self-regulation and lower peak levels of impulsivity/sensation seeking. Same sex peers represent a risk factor more for males than females during adolescence, while romantic partners increase risk for women during this developmental epoch. In summary, biologic factors, psychiatric co-morbidities as well as personality and environment present sex/gender-specific risks as adolescents begin to initiate substance use.

show abstract

Section: Sex/gender Differences In the Neurobiology Of Addictionmentioning

confidence: 99%

Emergence of sex differences in the development of substance use and abuse during adolescence

Kuhn

2015

Pharmacology & Therapeutics

148

109

View full text Add to dashboard Cite

show abstract

“…This suggests that decreased GABA is associated with heightened vulnerability toward cocaine abuse, while increased GABA may attenuate drug-taking behavior. Previous work indicates that EST inhibited activation of medium spiny GABAergic neurons in the striatum (Mermelstein et al, 1996), increased striatal GABA release (Hu et al, 2006), and enhanced dopamine metabolism and turnover (Di Paolo et al, 1985; Shimizu and Bray, 1993) and stimulant-elicited dopamine release in the striatum (Becker and Beer, 1986; Becker, 1990a, b; Castner et al, 1993). Conversely, PROG and its metabolites promoted striatal-GABA activity (Schumacher and McEwen, 1989, Schumacher et al, 1989) and decreased dopamine (Dazzi et al, 2002; Dluzen and Ramirez, 1984; Jaworska-Feil et al, 1998; Laconi et al, 2007; Shimizu and Bray, 1993) in the striatum.…”

Section: Progesterone Receptors and Sigma Receptorsmentioning

confidence: 99%

The role of progestins in the behavioral effects of cocaine and other drugs of abuse: Human and animal research

Anker

Carroll

2010

Neuroscience & Biobehavioral Reviews

View full text Add to dashboard Cite

This review summarizes findings from human and animal research investigating the influence of progesterone and its metabolites allopreganolone and pregnanolone (progestins) on the effects of cocaine and other drugs of abuse. Since a majority of these studies have used cocaine, this will be the primary focus; however, the influence of progestins on other drugs of abuse will also be discussed. Collectively, findings from these studies support a role for progestins in: 1) attenuating the subjective and physiological effects of cocaine in humans, 2) blocking the reinforcing and other behavioral effects of cocaine in animal models of drug abuse, and 3) influencing behavioral responses to other drugs of abuse such as alcohol and nicotine in animals. Administration of several drugs of abuse in both human and nonhuman animals significantly increased progestin levels, and this is explained in terms of progestins acting as homeostatic regulators that decrease and normalize heightened stress and reward responses which lead to increased drug craving and relapse. The findings discussed here highlight the complexity of progestin-drug interactions, and they suggest a possible use for these agents in understanding the etiology and developing treatments for drug abuse.

show abstract

“…The dopaminergic activity increases in response to exogenous administration of estradiol in rats. For example, in ovariectomized rats, estradiol increases dopamine synthesis [6, 7], turnover and release [e.g., 5, 8, 9], and DA receptor density [10, 11]. Estrogen also decreases monoamine oxidase activity, thereby regulating the degradation of DA [12].…”

Section: Introductionmentioning

confidence: 99%

Acute Effects of Estradiol Pretreatment on the Response to <i>d</i>-Amphetamine in Women

Justice

Wit²

2000

Neuroendocrinology

View full text Add to dashboard Cite

Little is known about the interactions between ovarian hormones and responses to psychoactive drugs in humans. Preclinical studies suggest that ovarian hormones such as estrogen and progesterone have direct and indirect central nervous system actions and that these hormones can influence behavioral responses to psychoactive drugs. In the present study, we assessed the subjective and physiological effects of d-amphetamine (AMPH; 10 mg p.o.) after pretreatment with estradiol. Two groups of healthy, regularly cycling women participated in two sessions scheduled during the early follicular phases of two menstrual cycles. One group received estradiol patches (Estraderm TTS; 0.8 mg) which elevated plasma estradiol levels to approximately 750 pg/ml on both sessions; the other group received placebo patches on both sessions. Both groups received AMPH (10.0 mg) and placebo in a randomized and counterbalanced order on the two sessions. Dependent measures included self-report questionnaires, physiological measures, and plasma hormone levels. Most of the subjective and physiological effects of AMPH were not affected by acute estradiol treatment. Nevertheless, estradiol pretreatment increased the magnitude of the effects of AMPH on subjective ratings of ‘pleasant stimulation’ and decreased ratings of ‘want more’. Also, estradiol produced some subjective effects when administered alone: It increased subjective ratings of ‘feel drug’, ‘energy and intellectual efficiency’, and ‘pleasant stimulation’. These results provide limited evidence that the stimulating effects of AMPH are increased by acute estradiol pretreatment.

show abstract

The influence of estrogen on nigrostriatal dopamine activity

Cited by 158 publications

References 27 publications

Emergence of sex differences in the development of substance use and abuse during adolescence

Emergence of sex differences in the development of substance use and abuse during adolescence

The role of progestins in the behavioral effects of cocaine and other drugs of abuse: Human and animal research

Acute Effects of Estradiol Pretreatment on the Response to <i>d</i>-Amphetamine in Women

Contact Info

Product

Resources

About